Abstract

Cannabinoids, the bioactive constituents of cannabis, exert a wide array of effects on the brain by engaging Type 1 cannabinoid receptor (CB1R). Accruing evidence supports that cannabinoid action relies on context-dependent factors, such as the biological characteristics of the target cell, suggesting that cell population-intrinsic molecular cues modulate CB1R-dependent signaling. Here, by using a yeast two-hybrid-based high-throughput screening, we identified BiP as a potential CB1R-interacting protein. We next found that CB1R and BiP interact specifically in vitro, and mapped the interaction site within the CB1R C-terminal (intracellular) domain and the BiP C-terminal (substrate-binding) domain-α. BiP selectively shaped agonist-evoked CB1R signaling by blocking an “alternative” Gq/11 protein-dependent signaling module while leaving the “classical” Gi/o protein-dependent inhibition of the cAMP pathway unaffected. In situ proximity ligation assays conducted on brain samples from various genetic mouse models of conditional loss or gain of CB1R expression allowed to map CB1R-BiP complexes selectively on terminals of GABAergic neurons. Behavioral studies using cannabinoid-treated male BiP+/− mice supported that CB1R-BiP complexes modulate cannabinoid-evoked anxiety, one of the most frequent undesired effects of cannabis. Together, by identifying BiP as a CB1R-interacting protein that controls receptor function in a signaling pathway- and neuron population-selective manner, our findings may help to understand the striking context-dependent actions of cannabis in the brain.SIGNIFICANCE STATEMENT Cannabis use is increasing worldwide, so innovative studies aimed to understand its complex mechanism of neurobiological action are warranted. Here, we found that cannabinoid CB1 receptor (CB1R), the primary molecular target of the bioactive constituents of cannabis, interacts specifically with an intracellular protein called BiP. The interaction between CB1R and BiP occurs selectively on terminals of GABAergic (inhibitory) neurons, and induces a remarkable shift in the CB1R-associated signaling profile. Behavioral studies conducted in mice support that CB1R-BiP complexes act as fine-tuners of anxiety, one of the most frequent undesired effects of cannabis use. Our findings open a new conceptual framework to understand the striking context-dependent pharmacological actions of cannabis in the brain.

Highlights

  • Preparations of the hemp plant Cannabis sativa L. have been used by humankind for millennia

  • BiP interacts with CB1 receptor (CB1R) in vitro To identify new CB1R-interacting intracellular proteins, we challenged the receptor’s carboxyl-terminal domain (CTD) to a cDNA library containing .106 different clones by means of a Y2H system

  • We show that BiP interacts with CB1R-CTD

Read more

Summary

Introduction

Preparations of the hemp plant Cannabis sativa L. have been used by humankind for millennia. There has been a strong renaissance in the study of the molecular and pharmacological bases of cannabinoid action; and, in concert, many countries have approved the use of cannabinoid-based medicines and standardized preparations of medicinal cannabis (Hill, 2015; Abrams, 2018). Both the therapeutic and the adverse effects of cannabis are mostly attributed to a single molecule, D9tetrahydrocannabinol (THC) (Mechoulam et al, 2014). It mediates a large number of pharmacological effects of THC, and, on binding endocannabinoids (anandamide and 2-arachidonoylglycerol), participates in the physiological control of multiple processes, such as motor behavior, learning and memory, fear and anxiety, pain, food intake, and energy metabolism (Piomelli, 2003; Mechoulam et al, 2014)

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.